2022

• patent2022/12/12

  European Patent Office Grants AskAt a Patent for the AAT-076 Production Process

  AskAt received the decision to grant a European patent dated November 30, 2022 from the European Patent Office (EPO) for a process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids. The notice was issued in connection with Application Number 20703096.6 (Filing Date: January 20, 2020).

• business2022/11/30

  Ikena Oncology Discontinues In-house Development of AAT-007

  On November 28, 2022, IKENA Oncology (IKENA; Boston, MA, USA), announced that they will discontinue internal clinical development of the EP4 antagonist IK-007(AAT-007) and will explore strategic alternatives. In addition, Ikena announced that they will present the results of the clinical study of IK-007 in combination with pembrolizumab (Keytruda®) in patients with unresectable or advanced microsatellite stable colorectal cancer in a poster at the 2022 European Society for Medical Oncology Immuno-Oncology Congress.

• patent2022/11/21

  U.S. Patent and Trademark Office Grants AskAt a Patent for AAT-076 Production Process

  AskAt received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) dated November 4, 2022 for a process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids. The Notice was issued in connection with Application Number 17/423,280 (Filing Date: January 20, 2020).

• patent2022/11/08

  Galliprant® Granted Supplementary Protection Certificate (SPC) in Great Britain (GB)

  GB granted SPC for Galliprant® on October 24, 2022, a veterinary drug product
  developed and marketed by Elanco Animal Health Inc. (Elanco). The SPC extends the period of exclusive sales rights for Galliprant® until February 28, 2031. The grant in GB marks the nineth approval in the EU, following grants received in Italy, Holland, Spain, Germany, France, Ireland, Greece, Poland, and GB.

• business2022/07/22

• patent2022/05/30

  Brazil’s National Institute of Industrial Property (Instituto Nacional da Propriedade Industrial: INPI) Grants AskAt a Patent for AAT-076 Formulation

  AskAt received a Notice of Allowance of a formulation patent for AAT-076, its COX-2 inhibitor. Application No. BR 11 2014 007568 9 (Filing Date: October 18, 2012) was published in the Brazilian Industrial Property Journal (Official Gazette) No: 2681 on May 24, 2022.

• patent2022/04/25

  China National Intellectual Property Administration (CNIPA) Grants AskAt an AAT-076 Formulation Patent

  AskAt received a Notice of Allowance dated April 7, 2022 for a formulation patent for AAT-076, its COX-2 inhibitor. The Notice was issued by the China National Intellectual Property Administration (CNIPA) in connection with Chinese Patent Application No. 201910582831.7 (Filing Date: October 18, 2012).

• patent2022/04/18

  Japan Patent Office Grants AskAt a Patent for the AAT-076 Production Process

  AskAt received an Official Decision of Grant from the Japan Patent Office dated April 12, 2022 for a process patent for AAT-076, entitled Process for the Differential Solubility-Driven Asymmetric Transformation of Substituted 2H-Chromene-3-Carboxylic Acids.

• ir2022/03/29

  9th period  financial statement release

  9th period  financial statement release